Tema Etfs LLC Cuts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Tema Etfs LLC has reduced its holdings in Regeneron Pharmaceuticals by 26.5%, now owning 4,300 shares valued at approximately $2.73 million.
• Regeneron reported $12.89 earnings per share for the last quarter, significantly exceeding analysts' expectations of $8.43, with a year-over-year revenue increase of 3.6%.
• Currently, institutional investors hold 83.31% of Regeneron’s stock, indicating strong institutional interest in the company.

Tema Etfs LLC lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 26.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,300 shares of the biopharmaceutical company's stock after selling 1,549 shares during the period. Tema Etfs LLC's holdings in Regeneron Pharmaceuticals were worth $2,727,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Pinney & Scofield Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $25,000. E Fund Management Hong Kong Co. Ltd. lifted its stake in shares of Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 31 shares during the last quarter. Costello Asset Management INC bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $27,000. Tompkins Financial Corp bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $32,000. Finally, Curat Global LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $32,000. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Up 0.2%

REGN stock traded up $1.09 during midday trading on Friday, hitting $580.70. The stock had a trading volume of 574,305 shares, compared to its average volume of 1,042,369. The firm has a market cap of $61.55 billion, a price-to-earnings ratio of 14.63, a price-to-earnings-growth ratio of 1.93 and a beta of 0.33. The business has a 50-day moving average of $557.26 and a two-hundred day moving average of $587.56. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,210.97. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping the consensus estimate of $8.43 by $4.46. The company had revenue of $3.68 billion for the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm's revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the prior year, the firm earned $11.56 earnings per share. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be paid a $0.88 dividend. The ex-dividend date is Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.87%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on REGN shares. JPMorgan Chase & Co. lowered their target price on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research note on Monday, June 9th. UBS Group restated a "neutral" rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Citigroup restated a "buy" rating and set a $650.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Guggenheim boosted their price target on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a report on Friday, August 1st. Finally, Truist Financial reduced their price target on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.